Normalization of the vasculature for treatment of cancer and other diseases. - sprookjes - yvandenbroek - TriplyDB

Normalization of the vasculature for treatment of cancer and other diseases.

Normalization of the vasculature for treatment of cancer and other diseases.

http://www.wikidata.org/entity/Q30471456

about

Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma Review on a Traditional Herbal Medicine, Eurycoma longifolia Jack (Tongkat Ali): Its Traditional Uses, Chemistry, Evidence-Based Pharmacology and Toxicology Vascular Wall-Resident Multipotent Stem Cells of Mesenchymal Nature within the Process of Vascular Remodeling: Cellular Basis, Clinical Relevance, and Implications for Stem Cell Therapy VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside The immunological effect of hyaluronan in tumor angiogenesis Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors Profile of bevacizumab and its potential in the treatment of cervical cancer Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?Hypoxic signaling during tissue repair and regenerative medicine Traversing the basement membrane in vivo: a diversity of strategies Vascular normalization and cancer immunotherapy Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads Compensatory angiogenesis and tumor refractoriness Targeting the intragraft microenvironment and the development of chronic allograft rejection RNA interference therapy: a new solution for intracranial atherosclerosis?Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.A systems biology view of blood vessel growth and remodelling Trial Watch:: Oncolytic viruses for cancer therapy Endothelial Rictor is crucial for midgestational development and sustained and extensive FGF2-induced neovascularization in the adult.Fibroblast Growth Factor 9 Imparts Hierarchy and Vasoreactivity to the Microcirculation of Renal Tumors and Suppresses Metastases The decidua-the maternal bed embracing the embryo-maintains the pregnancy Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.Tumor-induced solid stress activates β-catenin signaling to drive malignant behavior in normal, tumor-adjacent cells Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers T-type calcium channels blockers as new tools in cancer therapies Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI Fighting the force: Potential of homeobox genes for tumor microenvironment regulation Dietary Vitamin D and Its Metabolites Non-Genomically Stabilize the Endothelium Cardiovascular diseases related to ionizing radiation: The risk of low-dose exposure (Review)Sonoporation enhances liposome accumulation and penetration in tumors with low EPR.Dark field optical imaging reveals vascular changes in an inducible hamster cheek pouch model during carcinogenesis Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.

P2860

Q26740812-1AF03DD6-A5E9-4327-ABDB-85EFF50429F3 Q26746067-239CE116-D68B-45AB-AFA7-E26AFE4BDF1E Q26747666-BB8D03CE-47A3-4BA7-A2B0-264C5CCD18B6 Q26765484-45D0D558-5B83-484F-A17D-1F8251DE999C Q26765919-E2C242C1-C992-4725-9434-E10B2A1E4A33 Q26770678-80723EA5-67AB-4CAC-B6E4-383FE8CEC650 Q26771483-4EFC3CFF-C1CC-45B4-9528-7ED8BEEC1139 Q26773795-9C144AE3-D4F5-42A1-AD5C-D1A5F2F5614B Q26774168-8BA6AE9F-6CA9-4FF9-A94F-743B0FA2649A Q26777144-41BD33D0-70ED-4727-8E54-C3F9D7D0BCFA Q26778150-4616F82A-D6B1-448C-890C-11848853264F Q26824402-19466608-840A-4F67-A0AB-144689213327 Q26824769-A5EC11F8-35FB-4D51-A049-FF6531E0AE0B Q26827437-BF427080-E0B7-41AD-9548-37FC5D40583F Q26828930-1F3C7C8A-B096-48F1-88F7-6AA5F656306F Q26830075-65D1929A-1FB7-456F-BABC-67CC59E36752 Q26851916-BBF00292-F69D-4EED-B9C2-FB055D256C86 Q26852762-E63F2B41-359C-4604-8F79-0B1AE9951520 Q26860451-4529982E-72A4-4D7A-B156-F2203C5FE298 Q27000351-15EA6109-0566-4093-97A3-E5F8C90D3900 Q27002209-8108C805-F059-4848-BF1B-26DF0FB8531C Q27003945-F9C12E70-0791-4EDA-B601-0087DE1F1777 Q27021951-6DC3922E-D48A-429B-819D-E9F52843F556 Q27304564-631593B6-D018-4F16-A43A-87A275BD2058 Q27312628-2254EB42-1BDB-4725-914A-9198A4116A60 Q28069835-7476E2F8-76FC-48B4-BE70-E8122AE5D1F2 Q28073956-5D23EFB3-8F4E-4919-9335-FD2CEAA02237 Q28080530-438BD500-AA44-488E-BE30-004500DF59A6 Q28085029-386D4F75-FE44-4D62-9110-8BB2929B4F9C Q28118985-CB3ED4FA-D75F-4A96-89E6-F0165A3812B2 Q28306311-50897E55-205D-4ED5-AFCE-CBA6B335A1E4 Q28504783-33DB4603-2B89-47B3-BD65-E3FD56A309ED Q28540575-AD4D5F2C-0D50-40D9-931A-DC0D9EC55004 Q28547302-FF36996E-0516-4A3B-9A0E-B8E937D99F4D Q28550290-926924C1-1692-4476-8116-CE0074C41C54 Q30244472-3E3E928E-BA60-45E0-B102-6F51A1D3B9E1 Q30358121-C2EBBC05-BFA2-4566-9E68-BF3F381634B1 Q30372986-02FFB6C2-C202-4EEB-BBE9-9C8FF4D8BCE2 Q30383248-B4DE179B-CAA9-4F8B-B43A-51D1E880E7BA Q30399006-338C2F5E-E4F1-48D6-A0EF-306D9D784DA2

P2860

Normalization of the vasculature for treatment of cancer and other diseases.

http://www.wikidata.org/entity/Q30471456

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Normalization of the vasculature for treatment of cancer and other diseases.

@ast

Normalization of the vasculature for treatment of cancer and other diseases.

@en

type

label

Normalization of the vasculature for treatment of cancer and other diseases.

@ast

Normalization of the vasculature for treatment of cancer and other diseases.

@en

prefLabel

Normalization of the vasculature for treatment of cancer and other diseases.

@ast

Normalization of the vasculature for treatment of cancer and other diseases.

@en

P1433

Q30471456-1F8B178E-532E-40B9-BCCE-B99E6FF851AB

P1476

Q30471456-EE0D6CD8-F254-40F1-8D42-9029208102A9

P2093

Q30471456-06B97C15-3DFD-4711-81B5-759F27818F04

Q30471456-0945D94F-8B7C-4D93-90BE-D71875119F1D

Q30471456-1303B3E0-0B7C-4190-87F7-636550886039

Q30471456-35420E70-96BD-495C-A19E-DB37D7B0051C

Q30471456-C9F70A9D-E117-4589-8750-36935728F399

Q30471456-D324B607-B6FB-443D-B5C0-A88B6A6B1BE4

Q30471456-E13C2D8D-97EF-4C53-9ED1-045760D699AB

P2860

Q30471456-0073EEF6-78DD-4620-9A4C-0D0010472A6D

Q30471456-030F118F-EC45-487F-8F51-7DC1575A15A0

Q30471456-05071D15-028D-4CDD-AD04-FA90488C2F0A

Q30471456-067C77FF-61CB-484A-B668-B1E07C44DD0F

Q30471456-07252F81-B119-4FFF-BB8D-706C493CCFF7

Q30471456-074132CD-BF4D-43FA-B61A-025BA3762972

Q30471456-08271E58-91CF-4599-9A16-7DFAFADE151B

Q30471456-08DE3C59-AC22-4C8C-A014-6EA8308CC83F

Q30471456-0AFF1446-428A-4558-8642-87084F3FE9A1

Q30471456-0B2A17D4-58FC-42CF-BE02-958392CA1AA9

P304

Q30471456-0F03EF51-F1A2-40AE-8724-96AFC334F6E2

P31

Q30471456-FA4E7E0F-8ECA-4FB2-96D8-E9A6C7D2E063

P356

Q30471456-470F9C1B-68E0-4BB6-8332-F76F9FEDE389

P433

Q30471456-68C4D10B-7D3F-433A-86D8-DEFE872E0AB9

P478

Q30471456-37C2849F-2C5C-484C-93BF-5EAE324C8BF6

P577

Q30471456-0A3A774D-BF0A-4B53-9112-A4C01CB0F899

P5875

Q30471456-01EA337D-0046-4E93-B171-F8D31EE5867A

P698

Q30471456-CC7568BC-E636-45CA-A108-D57CD8C1AAF7

P932

Q30471456-C2024A02-5494-4C59-B0F4-485687F575DB

P356

PHYSREV.00038.2010

P1433

Physiological Reviews

P1476

Normalization of the vasculature for treatment of cancer and other diseases.

@en

P2093

Dai Fukumura

http://www.w3.org/2001/XMLSchema#string

Dan G Duda

http://www.w3.org/2001/XMLSchema#string

Lance L Munn

http://www.w3.org/2001/XMLSchema#string

Lei Xu

http://www.w3.org/2001/XMLSchema#string

Rakesh K Jain

http://www.w3.org/2001/XMLSchema#string

Shom Goel

http://www.w3.org/2001/XMLSchema#string

Yves Boucher

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of endothelium-derived nitric oxide production by the protein kinase Akt

Hallmarks of Cancer: The Next Generation

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation

Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane

P304

1071-1121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/PHYSREV.00038.2010

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

91

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51480356

http://www.w3.org/2001/XMLSchema#string

P698

21742796

http://www.w3.org/2001/XMLSchema#string

P932

3258432

http://www.w3.org/2001/XMLSchema#string